NGM Biopharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

NGM Biopharmaceuticals

02/03/2022 12:00

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 36 cents per share.
    * Revenue rose 6% to $20.96 million from a year ago; 
analysts
expected $20.20 million. 
    * NGM Biopharmaceuticals Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * NGM Biopharmaceuticals Inc shares had fallen by 18.2% this
quarter.
    * The company reported a quarterly loss of $27.23 million.
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $35.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 2 at 11:59 a.m.  ​All
figures in US dollars unless otherwise stated